Filing Details

Accession Number:
0001209191-14-078157
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-12-29 16:25:15
Reporting Period:
2014-12-23
Filing Date:
2014-12-29
Accepted Time:
2014-12-29 16:25:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1517022 Akebia Therapeutics Inc. AKBA Pharmaceutical Preparations (2834) 208756903
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1591098 Duane Nash C/O Akebia Therapeutics, Inc.
245 First Street, Suite 1100
Cambridge MA 02142
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-12-23 23,762 $11.54 23,762 No 4 A Direct
Common Stock Disposition 2014-12-24 6,764 $11.26 16,998 No 4 S Direct
Common Stock Disposition 2014-12-26 5,169 $11.19 11,829 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. 27,157 shares of restricted stock (as adjusted from 47,525 shares for the 1.75-for-1 stock split effected on March 6, 2014) was awarded on December 23, 2013. Fifty percent of the shares vested on December 23, 2014. The remaining fifty percent vest ratably on the first day of each calendar quarter over three years from the first anniversary of the grant date until fully vested, assuming continued service through the applicable vesting date.
  2. Price represents the selling price of the Issuer's common stock on December 23, 2014.
  3. Shares sold by reporting person pursuant to a 10b5-1 plan to pay taxes in connection with the vesting of restricted stock pursuant to the December 23, 2013 award described in footnote 1.
  4. The price reported in this Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $10.96 to $11.28, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.